Methionine Sulfoxide Suppresses Adipogenic Differentiation by Regulating the Mitogen‐activated Protein Kinase Signaling Pathway

Dani Qin,Yong Lei,Wen Xie,Qiuju Zheng,Zhou Peng,Yiwen Liu,Biao Dai,Tieliang Ma,Ping Wei,Chunlin Gao,Xirong Guo,Jianfang Gao,Jing Zhao,Juan Du,Qianyi Zeng,Zhongxiao Zhang,Xiaohua Dong,Huiping Shen
DOI: https://doi.org/10.1002/cbin.11964
IF: 4.473
2022-01-01
Cell Biology International
Abstract:In this study, methionine sulfoxide (MetO) was identified as an active metabolite that suppresses adipogenesis after screening obese individuals versus the normal population. MetO suppressed the gene and protein expression of CCAAT/enhancer binding protein (C/EBP) α, adipocyte fatty acid binding protein 4 (FABP4), and the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) during human preadipocyte (HPA) differentiation. Adipogenesis decreased following MetO treatment; however, the preadipocyte number, proliferation, and apoptosis were unaffected. The activity of phosphorylated extracellular signal-related kinase (P-ERK) of the mitogen-activated protein kinase (MAPK) pathway was significantly inhibited in HPA after MetO treatment. Furthermore, treatment of preadipocytes with the selective P-ERK1/2 agonist Ro 67-7476 abolished the effect of MetO against adipogenesis suggesting that MetO function is dependent on the MAPK pathway. The mechanistic insights of adipogenesis suppression by MetO presented in this study shows its potential as an antiobesity drug.
What problem does this paper attempt to address?